Download Files:
Buformin-d9 (hydrochloride)
SKU
HY-B2099S-1mg
Category Isotope-Labeled Compounds
Tags AMPK;Isotope-Labeled Compounds, Cancer; Metabolic Disease, Epigenetics;Others;PI3K/Akt/mTOR
Products Details
Product Description
– Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].
Web ID
– HY-B2099S
Shipping
– Room temperature
Molecular Formula
– C6H7D9ClN5
References
– [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res|[3]Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517.
Molecular Weight
– 202.73
SMILES
– N=C(N)NC(NC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=N.[H]Cl
Clinical Information
– No Development Reported
Research Area
– Cancer; Metabolic Disease
Solubility
– 10 mM in DMSO
Target
– AMPK;Isotope-Labeled Compounds
Pathway
– Epigenetics;Others;PI3K/Akt/mTOR
Product type
– Isotope-Labeled Compounds
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.